BioCentury | Jul 10, 2020
Finance

2Q20 Wrap: Biotech bounce

After the sudden, COVID-driven market declines that closed out 1Q20, biotech stocks rebounded in the second quarter with a force that has put shares up year to date. Many of the biggest moves came from...
BioCentury | Jun 20, 2020
Finance

Forma, Repare shine in first-day performances as biotech IPOs on NASDAQ maintain momentum

Three of four life sciences IPOs priced above expectations ahead of Friday’s session, and two biotechs in the group -- Forma and Repare -- posted big gains in their first trading day, showing continued strength...
BioCentury | Jun 17, 2020
Finance

Royalty’s $1.7B IPO latest sign of a biopharma market on a roll

Royalty Pharma priced the year’s second-largest biopharma IPO to date and then saw its shares rise nearly 60%, the latest sign of a robust appetite for fresh paper from life sciences companies. The investment firm’s...
BioCentury | Jun 3, 2020
Finance

Daily Chart: IPO queue grows to 20 life sciences companies

Twenty life sciences companies have lined up to make public debuts on U.S. and Asian exchanges, with Pliant Therapeutics Inc. expected to go first in a NASDAQ IPO Wednesday. The queue contains 13 companies seeking...
BioCentury | May 29, 2020
Finance

May 28 Quick Takes: Illumina leads $70M Ginkgo round; plus Arena, Viela Bio, BioCryst, Progenity and Microbion

Ginkgo financing to support COVID-19 testing New investor Illumina Inc. (NASDAQ:ILMN) led a $70 million round on Thursday for genetic engineering company Ginkgo Bioworks Inc.; existing investors General Atlantic and Viking Global Investors also participated....
BioCentury | May 2, 2020
Management Tracks

Catalent’s Boerman becomes president of cell and gene therapy; plus Stanford, Intellia, Cortexyme, CZ Biohub, Grail and more

Catalent Inc. (NYSE:CTLT) said Manja Boerman will become president of cell and gene therapy, succeeding Pete Buzy, who will continue as chairman of the gene therapy business. Boerman was president of the biotech’s European biologics...
BioCentury | Mar 6, 2020
Management Tracks

Sharp steps down as Ultragenyx CFO; plus Axsome, ElevateBio, FasterCures, Satsuma, WindMIL and more

...Inc. hired Patrick Fabbio as CFO, effective March 30. He is EVP and CFO at Progenics Pharmaceuticals Inc....
BioCentury | Dec 24, 2019
Company News

Dec. 23 Company Quick Takes: Theravance partners with Pfizer; plus Fortress-AZ, Progenics, Tracon-Alphamab Oncology-3D Medicines

...disorders. Fortress gained $0.17 to $2.47 on Monday. Progenics jumps on prostate cancer diagnostic data Progenics Pharmaceuticals Inc....
...primary endpoint with correct tumor localization rates of 85% to 87% with three independent evaluators. Progenics...
...membrane antigen Hongjiang Li, Staff Writer KN035, 3D-2-02-0015 Theravance Biopharma Inc. Pfizer Inc. Tracon Pharmaceuticals Inc. 3D Medicines Corp. Fortress Biotech Inc. AstraZeneca plc Progenics Pharmaceuticals Inc. Janus...
BioCentury | Nov 23, 2019
Company News

Management tracks: Sanofi head of strategy Mansuri set to retire; plus Arrakis, MorphoSys, Kymera, Kronos, Kite, Twist, Cerevel, Coda, Science 37, and more

...of trial oversight and informatics at ERT, a data and technology company. The board of Progenics Pharmaceuticals Inc....
...on Nov. 12, disclosed Baker's resignation in an SEC filing (see “Lantheus Enters Therapeutics with Progenics...
...Therapeutics Inc. Kronos Bio Inc. Arrakis Therapeutics Inc. Coda Biotherapeutics Inc. Kite Pharma Inc. Cerevel Therapeutics LLC Twist Bioscience Corp. Science 37 Inc. Progenics Pharmaceuticals Inc. Selecta...
BioCentury | Nov 14, 2019
Company News

Management tracks: Longtime Abbott CEO resigning; plus Otsuka, Bavarian Nordic, Progenics and Rakuten

...He was VP and global vaccines commercialization leader at GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). Cancer company Progenics Pharmaceuticals Inc....
...which has been under pressure from activist investor Velan Capital (see “Lantheus Enters Therapeutics with Progenics...
...and a group EVP at Rakuten Inc. Jonathan Block, Associate Editor Abbott Laboratories Bavarian Nordic A/S Otsuka Holdings Co. Ltd. Progenics Pharmaceuticals Inc....
Items per page:
1 - 10 of 724
BioCentury | Jul 10, 2020
Finance

2Q20 Wrap: Biotech bounce

After the sudden, COVID-driven market declines that closed out 1Q20, biotech stocks rebounded in the second quarter with a force that has put shares up year to date. Many of the biggest moves came from...
BioCentury | Jun 20, 2020
Finance

Forma, Repare shine in first-day performances as biotech IPOs on NASDAQ maintain momentum

Three of four life sciences IPOs priced above expectations ahead of Friday’s session, and two biotechs in the group -- Forma and Repare -- posted big gains in their first trading day, showing continued strength...
BioCentury | Jun 17, 2020
Finance

Royalty’s $1.7B IPO latest sign of a biopharma market on a roll

Royalty Pharma priced the year’s second-largest biopharma IPO to date and then saw its shares rise nearly 60%, the latest sign of a robust appetite for fresh paper from life sciences companies. The investment firm’s...
BioCentury | Jun 3, 2020
Finance

Daily Chart: IPO queue grows to 20 life sciences companies

Twenty life sciences companies have lined up to make public debuts on U.S. and Asian exchanges, with Pliant Therapeutics Inc. expected to go first in a NASDAQ IPO Wednesday. The queue contains 13 companies seeking...
BioCentury | May 29, 2020
Finance

May 28 Quick Takes: Illumina leads $70M Ginkgo round; plus Arena, Viela Bio, BioCryst, Progenity and Microbion

Ginkgo financing to support COVID-19 testing New investor Illumina Inc. (NASDAQ:ILMN) led a $70 million round on Thursday for genetic engineering company Ginkgo Bioworks Inc.; existing investors General Atlantic and Viking Global Investors also participated....
BioCentury | May 2, 2020
Management Tracks

Catalent’s Boerman becomes president of cell and gene therapy; plus Stanford, Intellia, Cortexyme, CZ Biohub, Grail and more

Catalent Inc. (NYSE:CTLT) said Manja Boerman will become president of cell and gene therapy, succeeding Pete Buzy, who will continue as chairman of the gene therapy business. Boerman was president of the biotech’s European biologics...
BioCentury | Mar 6, 2020
Management Tracks

Sharp steps down as Ultragenyx CFO; plus Axsome, ElevateBio, FasterCures, Satsuma, WindMIL and more

...Inc. hired Patrick Fabbio as CFO, effective March 30. He is EVP and CFO at Progenics Pharmaceuticals Inc....
BioCentury | Dec 24, 2019
Company News

Dec. 23 Company Quick Takes: Theravance partners with Pfizer; plus Fortress-AZ, Progenics, Tracon-Alphamab Oncology-3D Medicines

...disorders. Fortress gained $0.17 to $2.47 on Monday. Progenics jumps on prostate cancer diagnostic data Progenics Pharmaceuticals Inc....
...primary endpoint with correct tumor localization rates of 85% to 87% with three independent evaluators. Progenics...
...membrane antigen Hongjiang Li, Staff Writer KN035, 3D-2-02-0015 Theravance Biopharma Inc. Pfizer Inc. Tracon Pharmaceuticals Inc. 3D Medicines Corp. Fortress Biotech Inc. AstraZeneca plc Progenics Pharmaceuticals Inc. Janus...
BioCentury | Nov 23, 2019
Company News

Management tracks: Sanofi head of strategy Mansuri set to retire; plus Arrakis, MorphoSys, Kymera, Kronos, Kite, Twist, Cerevel, Coda, Science 37, and more

...of trial oversight and informatics at ERT, a data and technology company. The board of Progenics Pharmaceuticals Inc....
...on Nov. 12, disclosed Baker's resignation in an SEC filing (see “Lantheus Enters Therapeutics with Progenics...
...Therapeutics Inc. Kronos Bio Inc. Arrakis Therapeutics Inc. Coda Biotherapeutics Inc. Kite Pharma Inc. Cerevel Therapeutics LLC Twist Bioscience Corp. Science 37 Inc. Progenics Pharmaceuticals Inc. Selecta...
BioCentury | Nov 14, 2019
Company News

Management tracks: Longtime Abbott CEO resigning; plus Otsuka, Bavarian Nordic, Progenics and Rakuten

...He was VP and global vaccines commercialization leader at GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). Cancer company Progenics Pharmaceuticals Inc....
...which has been under pressure from activist investor Velan Capital (see “Lantheus Enters Therapeutics with Progenics...
...and a group EVP at Rakuten Inc. Jonathan Block, Associate Editor Abbott Laboratories Bavarian Nordic A/S Otsuka Holdings Co. Ltd. Progenics Pharmaceuticals Inc....
Items per page:
1 - 10 of 724